CDP 571. Anti-TNF monoclonal antibody, BAY 103356.

被引:0
作者
不详
机构
关键词
Ulcerative Colitis; Anti Tumour Necrosis Factor Alpha; Fast Track Designation; Expert Opin Investig Drug; Biologics License Application;
D O I
10.2165/00126839-199901030-00014
中图分类号
学科分类号
摘要
[No abstract available]
引用
收藏
页码:253 / 255
页数:2
相关论文
共 16 条
[1]  
Dhainaut JFA(1995)CDP571, a humanized antibody to human tumor necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock Crit Care Med 23 1461-9
[2]  
Vincent JL(1995)The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis Br J Rheumatol 34 334-42
[3]  
Richard C(1994)Anti TNF alpha treatment of a model of human ulcerative colitis Gut 35 50-12
[4]  
Rankin ECC(1994)Therapeutic applications of anti-TNF monoclonal antibodies Expert Opin Investig Drugs 3 907-4
[5]  
Choy EHS(1995)The treatment of ulcerative colitis with anti-tumour necrosis factor alpha antibody Falk Symposium Inflammatory Bowel Diseases 29 178-undefined
[6]  
Kassimos D(2063)Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn’s disease Scrip 1995 Sep 26 22-undefined
[7]  
Warren BF(1997)undefined Lancet 349 521-undefined
[8]  
Watkins PE(undefined)undefined undefined undefined undefined-undefined
[9]  
Foulkes R(undefined)undefined undefined undefined undefined-undefined
[10]  
Bloxham DP(undefined)undefined undefined undefined undefined-undefined